State Medicaid program; modifying appointment procedures for the Medicaid Drug Utilization Review Board. Effective date.
Summary
SB 927 makes targeted changes to the Medicaid Drug Utilization Review Board within the Oklahoma Health Care Authority. The bill updates the board’s membership appointment process, including how physician and pharmacist nominees are submitted, and clarifies the composition of the board’s ten members. It also preserves the board’s role in reviewing and advising on retrospective and prospective drug utilization programs, while updating several statutory terms and references for consistency.
Under the bill, the board continues to include four physicians, four pharmacists, one lay health care professional, and one pharmaceutical industry representative, but the nomination language is revised and the industry representative remains barred from voting on action items involving drugs or drug classes. The bill also keeps existing term limits and staggered terms, and it maintains requirements for geographic balance, open meetings, and rulemaking under the Administrative Procedures Act. The effective date is November 1, 2025.
Impact
SB 927 amends 63 O.S. 2021, Section 5030.1, affecting the statutory structure and appointment procedures for the Medicaid Drug Utilization Review Board. It does not change Medicaid eligibility or benefits directly, but it does alter how board members are nominated and appointed, which may affect oversight of prescription drug review policies and related administrative recommendations within the state Medicaid program.
Sentiment
The bill appears to have been generally supported in committee and on the floor, especially in the Senate where it passed unanimously through committee and third reading. In the House, it also advanced through both committees without opposition, but the final House third-reading vote was more divided, passing 56-31. Overall, the bill’s path suggests broad institutional support with some substantive concern at the chamber floor level.
Contention
The main point of contention appears to be the governance and composition of the Medicaid Drug Utilization Review Board rather than the Medicaid program itself. The revised nomination lists for physician and pharmacist members, the role of the pharmaceutical industry representative, and the voting restriction on that representative are the most likely areas of interest. The split House floor vote suggests some members may have been concerned about board structure, stakeholder influence, or the scope of changes to the appointment process, even though no committee opposition is reflected in the available record.